Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia

Clinical Lymphoma, Myeloma and Leukemia

Volumn 12, Issue 4, 2012, Pages 244-251

  Jabbour, Elias ^a   Garcia Manero, Guillermo ^a   Cortes, Jorge ^a   Ravandi, Farhad ^a   Plunkett, William ^a   Gandhi, Varsha ^a   Faderl, Stefan ^a   O'Brien, Susan ^a   Borthakur, Gautam ^a   Kadia, Tapan ^a   Burger, Jan ^a   Konopleva, Marina ^a   Brandt, Mark ^a   Huang, Xuelin ^a   Kantarjian, Hagop ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Acute myeloid leukemia; Efficacy; Refractory; Safety

Indexed keywords

CYTARABINE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER REGRESSION; CHRONIC MYELOID LEUKEMIA; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; EVENT FREE SURVIVAL; HAND FOOT SYNDROME; HUMAN; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; SALVAGE THERAPY; TREATMENT OUTCOME; TREATMENT RESPONSE; VEIN OCCLUSION; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLAST CRISIS; CYTARABINE; DISEASE-FREE SURVIVAL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; RECURRENCE; REMISSION INDUCTION; RISK FACTORS; SURVIVAL ANALYSIS; VIDARABINE; YOUNG ADULT;

EID: 84864225484     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2012.03.003     Document Type: Article

References (20)

1. E.H. Estey How I treat older patients with AML Blood 96 2000 1670 1673
2. V. Gandhi, E. Estey, M.J. Keating Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy J Clin Oncol 11 1993 116 124
3. V. Gandhi, E. Estey, M. Du Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia Clin Cancer Res 1 1995 169 178
4. V. Gandhi, E. Estey, M. Du Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy Clin Cancer Res 3 1997 1539 1545
5. E. Estey, W. Plunkett, D. Dixon Variables predicting response to high dose cytosine arabinoside therapy in patients with refractory acute leukemia Leucemia 1 1987 580 583
6. E.H. Estey, M.J. Keating, K.B. McCredie Cellular ara-CTP pharmacokinetics, response, and karyotype in newly diagnosed acute myelogenous leukemia Leucemia 4 1990 95 99
7. E. Estey Treatment of relapsed or refractory acute myelogenous leukemia Leucemia 14 2000 476 479
8. R.A. Larson, E.L. Sievers, E.A. Stadtmauer Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence Cancer 104 2005 1442 1452
9. A.K. Burnett, R.K. Hills, D. Milligan Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial J Clin Oncol 29 2011 369 377
10. F. Giles, S. O'Brien, J. Cortes Outcome of patients with acute myelogenous leukemia after second salvage therapy Cancer 104 2005 547 554
11. F. Ravandi, J. Cortes, S. Faderl Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy Blood 116 2010 5818 5823
12. E. Estey, W. Plunkett, V. Gandhi Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia Leuk Lymphoma 9 1993 343 350
13. G. Borthakur, H. Kantarjian, X. Wang Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival Cancer 113 2008 3181 3185
14. S.L. Price, J.E. Lancet, T.J. George Salvage chemotherapy regimens for acute myeloid leukemia: is one better? Efficacy comparison between CLAG and MEC regimens Leuk Res 35 2011 301 304
15. + primary resistant or relapsed acute myeloid leukemia Leuk Res 27 2003 893 897
16. S. Petersdorf, K. Kopecky, R.K. Stuart Preliminary results of Southwest Oncology Group Study S0106: An international intergroup phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to post-consolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia Blood 114 2009 abstract 790
17. H. Kantarjian, V. Gandhi, J. Cortes Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia Blood 102 2003 2379 2386
18. S. Faderl, S. Ravandi, G. Garcia-Manero Frontline therapy for older patients (pts) with acute myeloid leukemia (AML): clofarabine plus low-dose cytarabine induction followed by prolonged consolidation with clofarabine plus low-dose cytarabine alternating with decitabine Blood 116 2010 abstract
19. H.M. Kantarjian, G. Garcia-Manero, S. O'Brien Phase I clinical and pharmacokinetic studhy of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome J Clin Oncol 28 2010 285 291
20. S.R. Green, A.K. Choudhary, I.N. Fleming Combination of sapacitabine and HDAC inhibitors stimulates cell death in AML and other tumour types Br J Cancer 103 2010 1391 1399